PharmacyPharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyDrug Approval ProcessesCardiovascular DiseaseCardiovascular Drug SafetyCardiovascular PharmacologyDiabetes ManagementDiabetes PharmacotherapyRegulatory PharmacologyAdverse Cardiovascular Drug Events
Over 10 years after the diabetes drug rosiglitazone was approved by regulators, and despite studies on tens of thousands of people, questions remain about its cardiovascular safety. An investigation by the <i>BMJ</i> looks at why this happened.
2
The Risk of Fractures Associated with Thiazolidinediones: A Self-controlled Case-Series Study
Ian Douglas, Stephen Evans, Stuart Pocock et al. · PLoS Medicine · 2009 · 112 citations · Full text